Efficacy and Safety of Everolimus plus Exemetane in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer Patients

Everolimus and exemestane combination therapy represents a treatment option for estrogen receptor(ER)-positive metastatic breast cancer. We evaluated the efficacy and safety of everolimus and exemestane therapy, retrospectively. After a median follow-up of 10.5 months, the median progression-free su...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 44; no. 12; p. 1260
Main Authors Maeda, Noriko, Yamamoto, Shigeru, Sato, Yoko, Sakamoto, Kazuhiko, Suzuki, Nobuaki, Takeda, Shigeru, Nagashima, Yukiko, Kubo, Hidefumi, Nagano, Hiroaki
Format Journal Article
LanguageJapanese
Published Japan 01.11.2017
Subjects
Aged
Aged, 80 and over
Androstadienes - administration & dosage
Androstadienes - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Endocrine System
Everolimus - administration & dosage
Everolimus - adverse effects
Female
Humans
Middle Aged
Neoplasm Metastasis
Postmenopause
Online AccessGet more information

Cover

More Information
Summary:Everolimus and exemestane combination therapy represents a treatment option for estrogen receptor(ER)-positive metastatic breast cancer. We evaluated the efficacy and safety of everolimus and exemestane therapy, retrospectively. After a median follow-up of 10.5 months, the median progression-free survivalin patients was 4.7 months. The clinicalbenefit rate was 27%and the disease controlrate was 64%. The most common all-grade adverse events(AEs)were stomatitis(82%) and non-infectious lung disease(27%). The most commonB3 grade AEs were cellulitis(18%)and hyperglycemia(18%). The AEs reported were mostly grade 1 and 2, and manageable with appropriate intervention. Combination therapy with everolimus and exemestane appears to be a useful addition for ER-positive metastatic breast cancer, with carefulmanage- ment of specific AEs.
ISSN:0385-0684